GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Avricore Health Inc (OTCPK:AVCRF) » Definitions » YoY EBITDA Growth

Avricore Health (Avricore Health) YoY EBITDA Growth : 200.00% (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Avricore Health YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Avricore Health's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 200.00%.

Avricore Health's EBITDA per Share for the three months ended in Dec. 2023 was $0.00.


Avricore Health YoY EBITDA Growth Historical Data

The historical data trend for Avricore Health's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avricore Health YoY EBITDA Growth Chart

Avricore Health Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.25 53.57 -7.69 64.29 60.00

Avricore Health Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.00 50.00 -100.00 - 200.00

Avricore Health YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Avricore Health's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-0.002--0.005)/ | -0.005 |
=60.00 %

Avricore Health's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Sep. 2022 )) / | EBITDA per Share (Q: Sep. 2022 )) |
=(0.001--0.001)/ | -0.001 |
=200.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avricore Health YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Avricore Health's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Avricore Health (Avricore Health) Business Description

Traded in Other Exchanges
Address
1120 - 789 West Pender Street, Vancouver, BC, CAN, V6C 1H2
Avricore Health Inc is a Canada based company. The company is involved in the business of health data and point-of-care technologies. The Company has only one segment, being the HealthTab - Point of Care Business in Canada. The Company's revenues are generated from operating leases of the POCT system and sale of testing panels.

Avricore Health (Avricore Health) Headlines

From GuruFocus

Emerald Health Therapeutics Expands Strategic Investment in VANC

By Marketwired Marketwired 04-17-2018

Avricore Grants Options

By GlobeNewswire GlobeNewswire 08-11-2022

Avricore Health Extends Closing of Placement

By GlobeNewswire GlobeNewswire 07-20-2019

VANC Pharmaceuticals Inc. Provides Corporate Update

By GlobeNewswire GlobeNewswire 11-02-2018

VANC Announces Agreement for Acquisition of Corozon Platform

By GlobeNewswire GlobeNewswire 04-12-2018

Avricore Health Amends Options

By GlobeNewswire GlobeNewswire 09-11-2020